Sodium channel protein type 5 subunit alpha — Drug Target

All drugs that target Sodium channel protein type 5 subunit alpha — marketed and clinical-stage. Includes 7 drug classes acting on this target.

Drug classes

encainide · Amide Local Anesthetic · pirmenol · Standardized Chemical Allergen [EPC] · Non-narcotic Antitussive [EPC] · Anti-anginal [EPC] · Anti-epileptic Agent

Marketed (8)

• ENCAINIDE · encainide · Cardiovascular
• Naropin · Fresenius Kabi · Amide Local Anesthetic · Pain
• PIRMENOL · pirmenol · Cardiovascular
• Norcaine · Standardized Chemical Allergen [EPC] · Metabolic
• Decabid · Eli Lilly · Cardiovascular
• Tessalon · Generic (originally Pfizer) · Non-narcotic Antitussive [EPC] · Respiratory
• Ranexa · Menarini Intl · Anti-anginal [EPC] · Metabolic
  Ranexa works by blocking the sodium channels in heart muscle cells to reduce the amount of calcium that enters the cells during heart contractions.
• Cerebyx · Pfizer · Anti-epileptic Agent · Neuroscience
  Cerebyx works by stabilizing the inactivated state of sodium channels, preventing the rapid firing of neurons that can lead to seizures.